---
title: AI System Validation in GxP: A Practical Guide
date: 2026-11-07
description: How to validate an AI system in a GxP environment: intended use, risk, evidence, change control and monitoring, plus how AI can speed up validation itself.
author: Qualitum
cover: https://media.babylovegrowth.ai/blog-images/organization-48457/1793890875834_Automated-instrument-in-a-pharmaceutical-quality-laboratory.jpeg
coverAlt: Automated instrument in a pharmaceutical quality laboratory
---

Validating an AI system in a GxP environment means showing, with documented and risk-based evidence, that the system is fit for its intended use and stays that way across its life cycle. It builds on computerized system validation (CSV) and adds model-specific work: data fitness, performance boundaries for non-deterministic outputs, human oversight and monitoring. This guide walks through the steps, the regulatory picture in the US and EU, and the second question teams ask: how AI can shorten validation work itself.

## TL;DR

- AI plays two roles in GxP: it can be a system you must validate, and a tool that helps you perform validation. The two need different controls.
- Start with intended use and context of use. Risk, acceptance criteria and test design all follow from them.
- Risk rises with the AI's influence on the decision and the consequence of a wrong output. Human review of every output lowers it.
- Evidence must cover data, model, the complete system, and ongoing monitoring, with change control and defined revalidation triggers.
- Regulators are converging on risk-based, life cycle expectations, but the FDA and the EU document them differently.

## Table of Contents

- [Two meanings of "AI validation" in GxP](#two-meanings-of-ai-validation-in-gxp)
- [What validation of an AI system has to establish](#what-validation-of-an-ai-system-has-to-establish)
- [Step 1: Define intended use and context of use](#step-1-define-intended-use-and-context-of-use)
- [Step 2: Write requirements with performance criteria](#step-2-write-requirements-with-performance-criteria)
- [Step 3: Assess risk on impact and autonomy](#step-3-assess-risk-on-impact-and-autonomy)
- [Step 4: Build the evidence package](#step-4-build-the-evidence-package)
- [Step 5: Control change, retraining and drift](#step-5-control-change-retraining-and-drift)
- [What regulators expect in the US and EU](#what-regulators-expect-in-the-us-and-eu)
- [When AI helps you do the validation](#when-ai-helps-you-do-the-validation)
- [Our perspective](#our-perspective)
- [See it on your own systems](#see-it-on-your-own-systems)
- [FAQ](#faq)
- [Sources](#sources)

## Two meanings of "AI validation" in GxP

The keyword hides two different jobs. An [ISPE Pharmaceutical Engineering article from August 2026](https://ispe.org/pharmaceutical-engineering/ispeak/dual-role-ai-gxp-it-validation-validation-enabler-and-validation) describes AI's dual role: it can help perform validation work (the enabler) and it is a system that itself requires validation (the subject).

The distinction matters for your plan:

| | AI as validation subject | AI as validation enabler |
|---|---|---|
| Question | Is this AI-enabled system fit for its intended use in a GxP process? | Can AI draft, check and trace validation documents faster, without weakening evidence? |
| Example | A model that classifies deviations or flags batch anomalies | An agent that drafts URS, IQ/OQ/PQ protocols or reviews executed test evidence |
| Main risk | Wrong outputs affecting patient, product or data integrity | Unreviewed or untraceable AI-authored records entering the quality system |
| Key control | Intended use, performance criteria, monitoring, change control | Human review and signature, ALCOA+ checks, audit trail |

Most of this guide covers the first column. The last sections cover the second, because the same quality principles apply to both.

## What validation of an AI system has to establish

The same ISPE article defines AI-era validation as risk-based assurance that a system performs consistently within its defined intended-use range. It acknowledges non-deterministic outputs, so performance boundaries replace the fixed pass/fail of a deterministic function.

The [ISPE GAMP Guide: Artificial Intelligence](https://ispe.org/publications/guidance-documents/gamp-guide-artificial-intelligence), published in 2025, covers the life cycle of AI-enabled computerized systems, including the responsibilities of internal and external suppliers, with patient safety, product quality and data integrity as the aims. If your team already works from GAMP 5, this is the natural extension. Our [GAMP 5 validation guide](https://blog.qualitum.ai/gamp-5-validation) covers the base framework, and the [AI GAMP Agent](https://qualitum.ai/agents/gap) shows how categorization with its rationale can be documented.

## Step 1: Define intended use and context of use

Every later decision rests on this step. The FDA's draft credibility framework, as [summarized by DLA Piper](https://www.dlapiper.com/en-at/insights/publications/2025/01/fda-releases-draft-guidance-on-use-of-ai), starts by defining the question of interest and then the model's context of use: what is modeled, how outputs are used, and whether other information accompanies the output or the model is the sole step in answering the question.

A usable intended-use statement says:

- what the system does and, explicitly, what it does not do;
- who the users are and who holds decision authority (for example, the human reviewer enters the final decision and the model never finalizes it autonomously);
- which data, model version and configuration items are in scope;
- the operating environment and process step it supports.

Intended use also decides which regulatory status and controls apply, a principle that appears well beyond software, for instance in how [FDA approval and RUO materials](https://shopwithcaileys.com/fda-approval-does-not-apply-ruo-material) are treated differently depending on the stated purpose.

The ISPE guide's table of contents shows where this sits: the concept phase includes context of use and scope definition, drafting requirements, and an initial risk assessment with trustworthy AI considerations (see the [guide's contents](https://ispewebassets.org/files/publications/guidance-documents/2025-TOC/GAMP_Guide-AI_TOC.pdf)).

## Step 2: Write requirements with performance criteria

A conventional URS says what the system must do. For AI, add how well. Requirements should include:

- performance criteria, overall and for relevant subgroups of data;
- failure thresholds and how low-confidence outputs are handled;
- explainability needs, so a reviewer can verify the output against source information;
- record retention sufficient to reconstruct the regulated decision;
- monitoring data that exposes material changes in inputs, outputs, overrides, failures and deployed versions.

The EFPIA position paper on [AI in a GMP and manufacturing environment](https://www.efpia.eu/media/vqmfjjmv/position-paper-application-of-ai-in-a-gmp-manufacturing-environment-sept2024.pdf) (September 2024) says acceptance criteria belong in the requirement specifications and design qualification, so they exist before testing begins and cannot be fitted to results afterward. Our [requirements drafting use case](https://qualitum.ai/use-cases/drafting) shows how a first-draft spec can be generated with each line sourced.

## Step 3: Assess risk on impact and autonomy

The ISPE article on [AI governance in GxP environments](https://ispe.org/pharmaceutical-engineering/july-august-2024/artificial-intelligence-governance-gxp-environments) says overall risk should be determined by impact to patient, product and data integrity, and that lower-risk systems can implement only a subset of the recommended documents. That is proportionality, and it is how you avoid validating every chatbot like a sterile filling line.

Two frameworks give you concrete axes:

1. **FDA credibility assessment.** Per [DLA Piper's summary](https://www.dlapiper.com/en-at/insights/publications/2025/01/fda-releases-draft-guidance-on-use-of-ai), model risk combines model influence (how much the AI-derived evidence contributes relative to other evidence) and decision consequence (how significant an adverse outcome from a wrong decision would be). Scenarios where a human must review the output before deciding sit at lower risk, and use cases where AI makes a final determination without human intervention are treated as higher risk.
2. **EFPIA's GMP view.** The paper says the first step is deciding whether the AI application needs to be managed under GMP control, by looking at intended use and impact, the model's level of autonomy, and the extent of human intervention, with human in the loop as a key criterion.

A point worth documenting: as the [JPMA overview](https://www.jpma.or.jp/information/evaluation/results/allotment/nmeom8000000f0cn-att/EI_202604_fda_aicsve.pdf) of the FDA framework explains, "model risk" is not about bugs or security flaws in the algorithm. It is about how far later processes could harm patients, product quality or result reliability if they act on an incorrect output. The same source stresses that recording the evaluation axes and results against the context of use justifies your risk call and makes impact assessment easier when the context of use changes.

### A worked example

Take a model that suggests classification codes for deviation records, with a quality reviewer selecting the final code. Influence is moderate and a human reviews every output. Consequence is limited to a misclassified record that the reviewer can correct. That supports a lower-risk rating, with lighter documentation but still defined performance criteria and monitoring.

Now change the design so the model closes low-severity deviations automatically. Human review disappears and influence rises. The rating, the evidence and the controls all move up. The model is the same, but the context of use is different.

![Risk comparison for two deviation workflows](https://media.babylovegrowth.ai/blog-images/organization-48457/1793890903476_Risk-comparison-for-two-deviation-workflows.jpeg)

## Step 4: Build the evidence package

A defensible package combines classic CSV deliverables with model-specific evidence. A practical checklist:

- intended-use statement, risk assessment and supplier assessment;
- requirements with performance criteria, and design qualification showing how they will be met;
- data documentation: sources, selection, cleaning, splitting and justification for any exclusions;
- independent test data, protected from the development team;
- test results for the model and for the complete system including human review;
- release decision, monitoring plan and change-control procedure.

The EU's draft Annex 22 document is specific about test data. It says [test data should be protected by access controls](https://health.ec.europa.eu/document/download/5f38a92d-bb8e-4264-8898-ea076e926db6_en), that records should show which data was used for testing, when and how many times, and that cleaning or excluding test data should be documented and fully justified. Test documentation is retained with the intended-use description and test-data characterization.

The same document recommends explainability methods such as SHAP values, LIME attribution or heat maps to highlight which factors drive an outcome, with feature justification and defined confidence scores and thresholds. Reviewers can then see that the model decides on relevant features.

### Data fitness and integrity

Per an ISPE Pharmaceutical Engineering piece by Robert Stoop and Gaurav Walia on [GAMP AI guardrails](https://ispe.org/index.php/pharmaceutical-engineering/july-august-2026/transforming-pharmaceutical-quality-gampr-ai-guardrails), the GAMP AI guide expects data to be fit for purpose in its context of use: reliable, relevant, representative and abundant. The article adds that the guide sets principles and does not prescribe one way to apply them, so your validation plan must state how you apply them.

On integrity, EFPIA says data for AI/ML solutions must follow established principles such as ALCOA, backed by data validation, audit trails and integrity checks. If your team wants the integrity side in depth, see our guide to [MHRA data integrity for US teams](https://blog.qualitum.ai/mhra-data-integrity).

## Step 5: Control change, retraining and drift

This is where AI differs most from classic software. A [Drug Safety paper by Huysentruyt and colleagues](https://link.springer.com/article/10.1007/s40264-020-01030-2) notes that dynamic systems, which keep updating a model with new data, create stability and performance risks over time. It also argues that conventional validation and change-control guidance does not demonstrate consistent performance for such systems.

Practical controls:

- **Freeze what you validate.** Record model version, inference code version, preprocessing version and approved reference datasets as configuration items.
- **Define revalidation triggers up front.** Typical triggers are performance below threshold for a sustained period, material changes in input data sources or quality, retraining, infrastructure changes that could affect behavior, and shifts in regulatory expectations.
- **Retest periodically.** EFPIA calls for periodic retesting so the application keeps meeting its acceptance criteria.
- **Monitor overrides.** A rising rate of human overrides is an early signal that the model no longer matches reality.
- **Keep the audit trail complete.** Every output used in a regulated decision should be reconstructable.

## What regulators expect in the US and EU

The picture is not uniform, and a global company should attribute each expectation to its jurisdiction.

**United States.** A 2026 academic review of [AI validation and lifecycle governance](https://link.springer.com/article/10.1007/s43681-026-01218-9) describes the FDA's approach as predominantly non-binding guidance, including the January 2025 draft guidance on AI for regulatory decision-making for drugs and biologics. In January 2026 the FDA also published [Guiding Principles of Good AI Practice in Drug Development](https://www.fda.gov/media/189581/download), which lists 10 principles including human-centric design, a risk-based approach with proportionate validation, adherence to standards including GxP, clear context of use, data governance and documentation, and life cycle management.

**European Union.** The same review explains that the EU rests on the AI Act as a binding regulation, while revised Annex 11 and the new Annex 22 are expected to become enforceable expectations in GMP inspections once finalized. Draft Annex 22, launched for consultation in July 2025, is the first AI-specific GMP framework in the EU. It was drafted by the EMA GMDP Inspectors' Working Group with PIC/S, and the review notes that it excludes dynamic models from critical GMP applications.

The shared thread is clear: define the context of use, size validation to risk, keep humans accountable and manage the life cycle. Build to that common core, then add jurisdiction-specific requirements. For the current status of any draft, check the regulator's own page before you finalize a plan.

![What regulators expect in the US and EU](https://media.babylovegrowth.ai/blog-images/organization-48457/1793890944237_What-regulators-expect-in-the-US-and-EU.jpeg)

## When AI helps you do the validation

The second role, AI as validation enabler, is where much of the time goes today. Authoring URS, FS, IQ/OQ/PQ protocols, trace matrices and evidence reviews is repetitive and document-heavy, and it is the kind of work agents can draft.

The ISPE author offers a sensible test for adopting it: embed AI only where it genuinely supports the person reviewing the output. If correcting and verifying an AI draft takes nearly as long as writing it, stay manual. Judge each use case on that basis, and make sure of the following:

- the human reviewer holds the authority, and signatures remain theirs;
- each record is checked against ALCOA+ when written and when reviewed;
- the AI's sources are visible, so the reviewer verifies instead of trusting;
- the deployment keeps your data inside your infrastructure.

Our posts on [multi-agent validation](https://blog.qualitum.ai/multi-agent-validation) and [pharma validation automation with agentic ALCOA+ checks](https://blog.qualitum.ai/pharma-validation-automation) describe how this works and what to ask of any approach.

## Our perspective

> Validation teams are asked to do two things at once: approve AI that the business wants, and keep up with a documentation load that has not shrunk. The pressure behind both is the same, and it is easy to treat each as a separate project.
>
> We see them as one discipline. The principles that make an AI system defensible, which are a clear context of use, human accountability, traceable evidence and controlled change, are the same principles that make AI-authored validation records defensible. That is why we built our platform around them. Every record is ALCOA+ checked at write-time and at review-time, human signatures stay authoritative, and the platform is designed for private deployment inside your infrastructure with zero data egress.
>
> Our aim is to remove the documentation burden, not the judgment. Your validation lead should spend time on risk decisions and sign-off, while agents draft, trace and cross-check. Teams that start with a bounded system and a clear intended use learn quickly what good looks like, and then extend it.
>
> *Matt*

## See it on your own systems

If you are weighing how to speed up validation without giving up control, Qualitum's [Validate·AI and Operate·AI platform](https://qualitum.ai/platform) covers agent-authored validation across URS, FS, DQ, IQ, OQ and PQ, CSV/CSA and audit trails, with a live traceability matrix and integrations with major quality management systems.

![Qualitum](https://csuxjmfbwmkxiegfpljm.supabase.co/storage/v1/object/public/blog-images/organization-48457/1785522367413_qualitum.jpg)

We usually begin with a [paid pilot](https://qualitum.ai) on a defined scope, so your team can judge the output against your own templates and procedures. To see how our [technology](https://qualitum.ai/technology) fits your QA and InfoSec requirements, or to look at the [security model](https://qualitum.ai/security), start there.

## FAQ

### Does every AI tool used in a GxP company need full validation?

No. Validation effort should follow risk. The ISPE governance guidance says overall risk is set by impact to patient, product and data integrity, and lower-risk systems can implement a subset of the documents. Document your reasoning in the risk assessment so an inspector can follow it.

### How is validating an AI system different from validating conventional software?

Conventional validation tests deterministic behavior against fixed requirements. AI adds non-deterministic outputs, data dependence and possible drift, so you also define performance criteria and boundaries, test on independent data, and monitor after release. Change control must cover retraining and data changes, not just code.

### What is the role of human review in GxP AI?

It is a core risk control. The FDA framework treats cases where a human reviews and evaluates the output before a decision as lower risk, and use without human intervention as higher risk. Define who reviews, what they see, and who holds decision authority in the intended-use statement.

### Can AI-authored validation documents be used in an inspection?

The records must meet the same standards as any other: attributable, legible, contemporaneous, original, accurate and complete, with an audit trail and a human signature. Check each AI-authored record for ALCOA+ at creation and at review, and keep the reviewer in control of approval.

### Which guidance should we start with?

Start with the ISPE GAMP Guide: Artificial Intelligence for the life cycle, add the FDA's January 2026 principles and draft guidance for US expectations, and track draft EU Annex 22 and Annex 11 if you operate in Europe.

## Sources

- [The Dual Role of AI in GxP IT Validation (ISPE Pharmaceutical Engineering)](https://ispe.org/pharmaceutical-engineering/ispeak/dual-role-ai-gxp-it-validation-validation-enabler-and-validation)
- [ISPE GAMP Guide: Artificial Intelligence](https://ispe.org/publications/guidance-documents/gamp-guide-artificial-intelligence)
- [ISPE GAMP Guide: Artificial Intelligence, table of contents](https://ispewebassets.org/files/publications/guidance-documents/2025-TOC/GAMP_Guide-AI_TOC.pdf)
- [Key takeaways from FDA's draft guidance on use of AI (DLA Piper)](https://www.dlapiper.com/en-at/insights/publications/2025/01/fda-releases-draft-guidance-on-use-of-ai)
- [Application of AI in a GMP / Manufacturing environment (EFPIA)](https://www.efpia.eu/media/vqmfjjmv/position-paper-application-of-ai-in-a-gmp-manufacturing-environment-sept2024.pdf)
- [Artificial Intelligence Governance in GxP Environments (ISPE)](https://ispe.org/pharmaceutical-engineering/july-august-2024/artificial-intelligence-governance-gxp-environments)
- [Overview of the Risk-Based Credibility Assessment Framework (JPMA)](https://www.jpma.or.jp/information/evaluation/results/allotment/nmeom8000000f0cn-att/EI_202604_fda_aicsve.pdf)
- [Draft EU GMP Annex 22 document (European Commission)](https://health.ec.europa.eu/document/download/5f38a92d-bb8e-4264-8898-ea076e926db6_en)
- [Transforming Pharmaceutical Quality with GAMP AI Guardrails (ISPE)](https://ispe.org/index.php/pharmaceutical-engineering/july-august-2026/transforming-pharmaceutical-quality-gampr-ai-guardrails)
- [Validating Intelligent Automation Systems in Pharmacovigilance (Drug Safety)](https://link.springer.com/article/10.1007/s40264-020-01030-2)
- [Validation, ethics, and lifecycle governance of AI (Springer)](https://link.springer.com/article/10.1007/s43681-026-01218-9)
- [Guiding Principles of Good AI Practice in Drug Development (FDA)](https://www.fda.gov/media/189581/download)

## Recommended

- [Multi-Agent Validation in GxP: How It Works and What to Ask](https://blog.qualitum.ai/multi-agent-validation)
- [Configurable vs Custom Validation in GxP Systems](https://blog.qualitum.ai/configurable-vs-custom-validation)
- [GAMP 5 Validation: A Practical Guide for Quality Teams](https://blog.qualitum.ai/gamp-5-validation)
- [Qualification vs Validation: A Practical Guide for Pharma QA](https://blog.qualitum.ai/qualification-vs-validation)

## FAQ
### Does every AI tool used in a GxP company need full validation?
No. Validation effort should follow risk. The ISPE governance guidance says overall risk is set by impact to patient, product and data integrity, and lower-risk systems can implement a subset of the documents. Document your reasoning in the risk assessment so an inspector can follow it.

### How is validating an AI system different from validating conventional software?
Conventional validation tests deterministic behavior against fixed requirements. AI adds non-deterministic outputs, data dependence and possible drift, so you also define performance criteria and boundaries, test on independent data, and monitor after release. Change control must cover retraining and data changes, not just code.

### What is the role of human review in GxP AI?
It is a core risk control. The FDA framework treats cases where a human reviews and evaluates the output before a decision as lower risk, and use without human intervention as higher risk. Define who reviews, what they see, and who holds decision authority in the intended-use statement.

### Can AI-authored validation documents be used in an inspection?
The records must meet the same standards as any other: attributable, legible, contemporaneous, original, accurate and complete, with an audit trail and a human signature. Check each AI-authored record for ALCOA+ at creation and at review, and keep the reviewer in control of approval.

### Which guidance should we start with?
Start with the ISPE GAMP Guide: Artificial Intelligence for the life cycle, add the FDA's January 2026 principles and draft guidance for US expectations, and track draft EU Annex 22 and Annex 11 if you operate in Europe.
